The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
暂无分享,去创建一个
Yuan-Tsong Chen | R. Finkel | Yuan-Tsong Chen | A. Rosenberg | P. Kishnani | R. Ladda | Suhrad G Banugaria | Sean N Prater | Yiu-Ki Ng | Joyce A Kobori | Richard S Finkel | Roger L Ladda | Amy S Rosenberg | Priya S Kishnani | Sean N. Prater | S. Banugaria | Y. Ng | J. Kobori
[1] N. Casadevall. Antibodies against rHuEPO: native and recombinant. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] J. Clancy,et al. Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease , 2009, Pediatric Research.
[3] T. Choudhury,et al. Glycogen storage disease (type-III). , 1991, Indian pediatrics.
[4] B. Byrne,et al. Recombinant human acid α-glucosidase , 2007, Neurology.
[5] C. Kempton,et al. How we treat a hemophilia A patient with a factor VIII inhibitor. , 2009, Blood.
[6] J. Darrah,et al. Motor Assessment of the Developing Infant , 1994 .
[7] B. Thurberg,et al. Differential muscular glycogen clearance after enzyme replacement therapy in a mouse model of Pompe disease. , 2007, Molecular genetics and metabolism.
[8] J. Belmont,et al. Enzyme-replacement therapy in mucopolysaccharidosis I. , 2001, The New England journal of medicine.
[9] T. Voit,et al. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial , 2005, Neuromuscular Disorders.
[10] W. Hoots,et al. Advances in hemophilia: experimental aspects and therapy. , 2010, Hematology/oncology clinics of North America.
[11] Yuan-Tsong Chen,et al. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry. , 2003, Analytical biochemistry.
[12] A. Rosenberg,et al. Elimination of antibodies to recombinant enzyme in Pompe's disease. , 2009, The New England journal of medicine.
[13] D. Millington,et al. Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease. , 2000, Analytical biochemistry.
[14] H. Mandel,et al. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. , 2010, Molecular genetics and metabolism.
[15] A. Pestronk,et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. , 2010, The New England journal of medicine.
[16] D. Brooks,et al. Enzyme Replacement Therapy in Mucopolysaccharidosis I: Altered Distribution and Targeting of α-l-Iduronidase in Immunized Rats , 2000 .
[17] M. Vogel,et al. Left ventricular myocardial mass determined by cross-sectional echocardiography in normal newborns, infants, and children , 1991, Pediatric Cardiology.
[18] M. Kroos,et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. , 2010, Molecular genetics and metabolism.
[19] J. Charrow,et al. Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial , 2001, Genetics in Medicine.
[20] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[21] M. Knip,et al. Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. , 1988, Diabetes research.
[22] D. Koeberl,et al. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. , 2007, American journal of human genetics.
[23] S. Marie,et al. Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: “To See a World in a Grain of Sand…” , 2007, Autophagy.
[24] C. Rougeot,et al. Comparative study of biosynthetic human growth hormone immunogenicity in growth hormone deficient children. , 1991, Hormone research.
[25] Wuh-Liang Hwu,et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. , 2006, The Journal of pediatrics.
[26] C. Wanner,et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. , 2008, Molecular genetics and metabolism.
[27] J. McPherson,et al. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. , 1993, Blood.
[28] W. Hop,et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. , 2003, Pediatrics.
[29] S. Richards. Immunologic considerations for enzyme replacement therapy in the treatment of lysosomal storage disorders , 2002 .
[30] M. Mcentee,et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. , 2008, The Journal of clinical investigation.
[31] B. Byrne,et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. , 2007, Neurology.
[32] R. Herndon,et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis , 1998, Neurology.
[33] G. Herman,et al. Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. , 2006, The Journal of pediatrics.
[34] G. Hug. Pre- and postnatal pathology, enzyme treatment, and unresolved issues in five lysosomal disorders. , 1978, Pharmacological reviews.
[35] N. Raben,et al. Induction of Tolerance to a Recombinant Human Enzyme, Acid Alpha-Glucosidase, in Enzyme Deficient Knockout Mice , 2003, Transgenic Research.
[36] B. Byrne,et al. Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease , 2009, Genetics in Medicine.
[37] C. Hollak,et al. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome? , 2009, Molecular genetics and metabolism.
[38] S Porter,et al. Human immune response to recombinant human proteins. , 2001, Journal of pharmaceutical sciences.